GlassScriptPhysician profile
Sarah L Jaspers
NPI 1467780437
$10,890.81
in general payments reported to CMS, 2019-2025
50 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,027 · 2022: $2,562 · 2023: $1,667 · 2024: $2,049 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.03 | 2021-2025 | |
| Novo Nordisk INC | $1,152.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,009.63 | 2021 | |
| Glaxosmithkline, LLC. | $951.73 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $842.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.16 | 2021-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $468.17 | 2021-2025 | Assurity, Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $388.03 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $360.88 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.42 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $350.93 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $330.47 | 2022-2025 | |
| Daiichi Sankyo INC. | $321.88 | 2021-2023 | Injectafer |
| Dexcom, INC. | $230.89 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $230.12 | 2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $203.33 | 2021-2024 | |
| Amgen INC. | $169.14 | 2022-2024 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $151.40 | 2022-2025 | General - Pain Management, Watchman Access System |
| Merck Sharp & Dohme LLC | $129.97 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $122.99 | 2023-2025 | |
| Exact Sciences Corporation | $113.56 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $109.21 | 2021-2024 | Vpriv, Trintellix |
| Intuitive Surgical, INC. | $90.08 | 2022-2023 | |
| Amarin Pharma, INC. | $86.51 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $47.82 | 2023 | Gvoke Hypopen |
| Corcept Therapeutics | $47.66 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $42.11 | 2022 | |
| Phathom Pharmaceuticals, INC. | $36.67 | 2024-2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.54 | 2021 | |
| Dynavax Technologies Corporation | $32.64 | 2023 | Heplisav-B |
| Medtronic, INC. | $31.03 | 2022 | |
| Surgenex LLC | $29.40 | 2025 | Surmatrix, Pellograft, Surgraft |
| Lucid Diagnostics INC. | $29.22 | 2022 | |
| Currax Pharmaceuticals LLC | $28.33 | 2023-2024 | Contrave, Onzetra Xsail |
| Nevro Corp. | $27.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.10 | 2025 | Rexulti |
| Redhill Biopharma INC. | $24.95 | 2021 | |
| Hologic Sales and Service, LLC | $24.39 | 2024 | Aptima |
| Esperion Therapeutics, INC. | $24.09 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $22.11 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.00 | 2025 | Pyrukynd |
| Seqirus USA INC | $20.21 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Ascensia Diabetes Care US INC. | $17.80 | 2022 | |
| Baxter Healthcare | $17.45 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Davol INC. | $17.17 | 2024 | Phasix Mesh |
| Hikma Pharmaceuticals USA | $17.14 | 2021 | |
| Eisai INC. | $17.04 | 2021 | |
| Alfasigma USA, INC. | $16.92 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.95 | 2023 | Quviviq |
| Vistapharm, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jaspers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.